Belantamab Mafodotin-blmf: A Novel Antibody-Drug Conjugate for Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Multiple myeloma (MM) is a hematologic malignancy characterized by proliferation of plasma cells with or without production of monoclonal immunoglobulins. Management of patients with MM begins with induction therapy, typically a proteasome inhibitor (PI) with dexamethasone and an immunomodulator (IM...

Descripción completa

Detalles Bibliográficos
Autores principales: Ketchum, Emily Behren, Clarke, Andrea, Clemmons, Amber B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2022
Materias:
Prescriber's Corner
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805802/
https://www.ncbi.nlm.nih.gov/pubmed/35173991
http://dx.doi.org/10.6004/jadpro.2022.13.1.7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805802/
https://www.ncbi.nlm.nih.gov/pubmed/35173991
http://dx.doi.org/10.6004/jadpro.2022.13.1.7

Ejemplares similares